Emergent BioSolutions Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| EBS | CJH.F | AMPH | HESTERBIO.BO | 300601.SZ | MEGA.BK | |
|---|---|---|---|---|---|---|
| Market cap | 303.35M | 755.95M | 1.19B | 20.58B | 14.41B | 30.95B |
| P/E (TTM) | — | 153.0 | 16.6 | 15.0 | 117.3 | 14.2 |
| Forward P/E | 5.6 | — | 8.8 | 45.4 | 45.0 | 12.4 |
| Price/book | 1.0 | 1.1 | 1.6 | 5.7 | 1.5 | 3.0 |
| Dividend yield | — | — | — | 0.47% | 0.49% | 4.86% |
| 1-year change | −42.55% | −41.70% | +15.64% | +45.65% | −25.16% | +20.69% |
| Today | −5.60% | +6.25% | +3.32% | +4.34% | +1.57% | +1.43% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All EBS news ›Emergent BioSolutions Receives $22.3 Million Delivery Order Modification to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War
Emergent BioSolutions Receives $22.3 Million Delivery Order Modification to Supply BioThrax Business Wire Emergent BioSolutions Receives $22.3 Million Delivery Order Modification to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S.…
Emergent BioSolutions: 3 Key Takeaways for Long-Term Investors
NARCAN's market lead persists despite pricing pressure, signaling the brand's resilience as the company executes its turnaround. Management restructured operations in August to bring spending in line with lower commercial revenue. The cuts…
Emergent Biosolutions Reports Third Quarter 2026 Financial Results
Q3 2026 vs. Q3 2025 Adjusted Net Income (Loss) per Diluted Share (2) Year to Date ("YTD") 2026 vs YTD 2025 Adjusted Net Income (2) Adjusted Net Income per Diluted Share (2) Net Income (Loss) Margin Adjusted EBITDA Margin (2) THIRD QUARTER…
More from 1 other outlet
Emergent BioSolutions (EBS) Q3 2026 Earnings Call Transcript
Revenue fell 52% on delivery timing, but debt dropped 55% and guidance rose on margins. Operator: Hello, everyone. Thank you for joining us, and welcome to the Emergent BioSolutions Third Quarter 2026 Earnings Call. [Operator Instructions]…
Emergent Biosolutions: Q3 Earnings Snapshot
GAITHERSBURG, Md. (AP) — GAITHERSBURG, Md. (AP) — Emergent Biosolutions Inc. (EBS) on Monday reported a loss of $32.7 million in its third quarter. On a per-sha On a per-share basis, the Gaithersburg, Maryland-based company said it had a…
Emergent BioSolutions Inc. 2026 Q3 - Results - Earnings Call Presentation
2026-11-03. The following slide deck was published by Emergent BioSolutions Inc. The following slide deck was published by Emergent BioSolutions Inc. in conjunction with their 2026 Q3 earnings call.
Emergent Biosolutions Sees IBD RS Rating Rise To 73
A Relative Strength Rating upgrade for Emergent Biosolutions shows improving technical performance. Will it continue? Emergent Biosolutions (EBS) saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, with an increase…
Comparing Emergent Biosolutions (NYSE:EBS) & Monte Rosa Therapeutics (NASDAQ:GLUE)
Posted by Kim Johansen on Oct 21st, 2026 Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) and Emergent Biosolutions (NYSE:EBS – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will…
Emergent BioSolutions Announces CFO Transition Amid Transformation
Emergent Biosolutions ( (EBS) ) has shared an update. Emergent BioSolutions announced on October 16, 2026, that longtime chief financial officer Richard S. Lindahl will retire from his role on December 31, 2026, after nearly nine years at…
Emergent BioSolutions Announces Retirement of Chief Financial Officer Richard S. Lindahl
Emergent BioSolutions Inc. today announced that Richard S. Lindahl, executive vice president, chief financial officer, will retire from the Company effective December 31, 2026. Frank Vargo, vice president, treasurer, will assume the role…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com13
- seekingalpha.com2
- stocktitan.net2
- themarketsdaily.com2
- biospace.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 24 articles, not a forecast.